Aug. 13, 2013
/PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the Board of Directors of PharMerica Corporation ("PharMerica" or the "Company") (NYSE: PMC) concerning possible breaches of fiduciary duty and other violations of law. The investigation concerns actions by PharMerica's Board of Directors that have allegedly caused the Company to violate the False Claims Act ("FCA") and the Controlled Substances Act ("CSA").
August 9, 2013
the Department of Justice announced that it had filed a suit against PharMerica for violating the FCA and the CSA by dispensing controlled substances without valid prescriptions and causing claims for illegally dispensed drugs to be submitted for reimbursement under the Medicare program. The government's complaint alleges that PharMerica routinely dispensed Schedule II controlled substances in non-emergency situations without first obtaining a written prescription from a treating physician. The complaint alleges that PharMerica knowingly caused the submission of false claims to Medicare for these improperly dispensed Schedule II drugs, in violation of the FCA.
Shareholders interested in seeking to recover damages on behalf of PharMerica and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
Request more information now by clicking here: www.faruqilaw.com/PMC
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.
If you hold PMC shares and you would like to discuss your legal rights, visit
. You can also contact us by calling
Michael J. Hynes
free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to